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AND DEXTROMETHORPHAN HBR 
 
Abstract 
Pseudoephedrine HCL, Guaifenesin, Chlorpheniramine Maleate and Dextromethorphan HBr 
combination is a common combination cough syrup. The chemical analysis of each individual 
component is efforts and time consuming. HPLC method had been develop for simultaneous 
determination of the four compounds in one HPLC injection of 20 µl using detector at 210 nm, 
column C18 4.6 mm × 250 mm, 3µm and mobile phase of Potassium dihydrogen 
orthophosphate, acetonitrile, orthophosphoric acid , triethanolamine and water . At column oven 
temperature of 40 ͦC, flow rate 0.8 ml/min and 60 minutesrun time. The method had been 
evaluated for system suitability and validated according to the ICH guidelines with respect to 
method specificity, linearity and range, precision, accuracy and robustness. Limit of detection 
quantitation limit and solution stability had been assessed. The results showed that the method 
fulfilled all acceptable criteria for all validation parameters. It had been recommended that the 
method can be used for routine analysis of products containing the four components. 
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Introduction 
Validation of an analytical procedure is the process by which it isestablished, by laboratory 
studies, that the performance characteristics of the procedure meet the requirements for the 
intended analytical application
1
.As per the ICH guidelines, the validation process of the method 
includes the specificity, linearity and range, precision, accuracy, solution stability, assay of 
pharmaceutical product and robustness
2
. 
Compounds structural formula
3
: 
 
 
Figure 1: the structural formulas of the compounds 
Pseudoephedrine is a systemic decongestant, Quiafenesin C10H4O4is used as expectorant and to 
liquefy the bronchial secretion, chlorpheniramine is used for symptomatic relief of allergy, and 
dextromethorphan is a cough suppressant
4
. The USP HPLC method for its individual assay uses 
water/ methanol/glacial acetic acid as mobile phase, 4.6 mm×250 mm column packed with L1 
10µm, 276 nm detector and 2ml/min rate flow. The retention time is 7 mins.
1
 
The USP method for assay of solution three or more of Acetaminophen, Chlorpheniramine 
Maleate, Dextromethorphan HBr and Pseudoephedrine HCL uses menthol/ water, monobasic 
potassium phosphate, triethylamine, sodium lauryl sulphate and phosphoric acid as mobile phase. 
Column 4.6 mm×150 mm,L11, 214 nm detector and 2m/min flow rate 
1
.Many studies to 
Chlorpheniramine Guaifenesin Dextromethorphan  Pseudoephedrine   
 
 
 
asaayGuaifenesin alone and in combination of other drugs had been done using 
Spectrophotometric methods and HPLC methods 
5
. 
The objective is to validate a method for quantitative determination of Pseudephedrine HCL, 
Guaifensin, Chlorpheniramine Maleate and Dextromethorphan HBr simultaneously in one single 
HPLC injection. 
Materials and Methods 
Materials 
Purified water, Blue Nile research Centre, Sudan. Potassium DihydrogenOrthophophate, 
ScharlauChemie, Spain.Acetonitrile HPLC grade, SharlauChemie, Spain.Triethanolamine 99.8% 
AR, Chem lab NV; Belgium.Orthophosphoric acid 88% LubaChemie, India. 
Chlorpheniramine Maleate, Guiafensin, Dextromethorphan hydrobromide and Pseudoephedrine 
working standards.AD test samples. 
Instruments 
High Performance Liquid Chromatography, Prominece – LC 2030, Shimatsu, Japan.Software 
Lab solution, Shimatsu, Japan.Column ; insert Sustain C18; 4.6 mm× 250 mm; 3 µm. Electronic 
Balance AY 220, Schimatsu. pH meter Mi 150; Hanna instruments, Romania. Rocking Shaker 
SK-330-pro, USA.Sonicator 621.05.003 IsolabograreGmpH instruments, Germany. 
Chromatographic System 
Column: insert Sustain C18; 4.6 mm× 250 mm; 3 µm. Flow rate: 0.8 ml/min. wave length 210 
nm. Detector: PDA/UV. Oven temperature: 40 ͦC. Injection volume: 20 µL. Run time: 60 min. 
Preparation of 0.2 M Potassium dihydrogen orthophosphate: dissolve 27.218 gram in 700 ml 
water and complete to 1000 ml. 
Preparation of mobile phase: to 550 ml of 0.2 M Potassium dihydrogen Orthophosphate in a 1 
litre volumetric flask add 200 ml of Acetoniltrile, 30 ml of 10% Orthophosphoric acid and 1 ml 
Triethanolamine 99.8%. Dilute to volume by water and adjust the pH to 3 with orthophosphoric 
acid or Sodium hydroxide. 
Preparation pf diluent: use the mobile phase as a diluent. 
Preparation of the Standard: 100 mg Guiafenesin, 30 mg Pseudoephedrine HCL, 10 mg 
Dextromethorphan and 2 mg chlorpheniramine Maleate working standards into 100 ml 
volumetric flask, add 60 diluent,shake and sonicate for 5 minutes, cool and make up to volume 
with diluent. Mix well, transfer to 10 ml to 50 ml volumetric flask make up to volume with the 
dilueny, mix and filter using 0.45 µL nylon syringe filter. 
Preparation of the Sample: Transfer 2 ml of the sample of specific gravity 1.2779 g/cm
3
= 2.5558 
grams to 100 m volumetric flask, add 60 ml diluent, shake well for 10 minutes, make up to 
volume with diluent, filter using0.45 µL nylon syringe filter.  
Procedure 
Equilibrate the column with mobile phase for sufficient time until stable baseline is obtained. 
Separately inject equal volumes 20µL of the standard preparation and the assay preparation into 
the chromatographic system, record the chromatogram and measure the areas of the major peaks. 
Inject the blank once, the standard solution for 6 replicates and the sample preparation  in 
triplicates. 
The tailing factor for each peak should not be more than 2 and the RSD should not be more than 
2. Calculate the quantity in percentage by the formula: 
Ru/Rs×C×(100/Wu)×D×P/100×1/L×100where, D is the density in mg/ml, Wu is the weight in 
mg of the sample taken, Ru and Rs are the peak areas responses from the assay preparation and 
 
 
 
the standard preparation respectively, P is the potency of tested API in % and L is the labeled 
quantity. 
 
Steps on Method Validation 
6,7
 
1. Develop a validation protocol or operating procedure for the validation. 
2. Define the application, purpose, and scope of the method. 
3. Define the performance parameters and acceptance criteria. 
4. Define validation experiments. 
5. Verify relevant peformance characteristics of equipment. 
6. Qualify materials (e.g., standards and reagents). 
7. Perform prevalidation experiments. 
8. Adjust method parameters or/and acceptance criteria if necessary. 
9. Perform full internal (and external) validation experiments. 
10. Develop SOPs for executing the method in the routine. 
11. Define criteria for revalidation. 
12. Define type and frequency of system suitability tests and/or analytical quality control 
(AQC) checks for the routine. 
13. Document validation experiments and results in the validation report. 
 
Results and Discussion 
 
Precision  
System suitability 
The following table presents the average of 6 injection of the standard 
 
Figure 2: Chromatogram for System Suitability 
 
 
 
 
Table (1) Results of the Method Precision 
 
 
 
6 replicates Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
Average RT 
RSD% 
5.5 mins 12.63 mins 15.85 50.44 
0.07 0.05 0.08 0.07 
Average Area 
RSD% 
2850535.33 11585256.33 201544.17 936327 
0.04 0.04 0.19 0.05 
Plates 46780 72286.83 79354 81109.17 
Tailing factor 1.38 1.27 1.28 1.23  
Peaks 
resolution 
- 20.47 5.6 28.65 
The RSD% for the retention timesand he peaks areas of all substances is less than 1%, the 
theoretical plates is more than 2000, the tailing factors are more than 2 and the resolution 
between the peaks is more than 2. Thus complying the precision acceptance criteria. 
Specificity  
Using placebo suspension in the same weight and way of the sample test, following the same 
procedure, no interference from the placebo was observed at the retention time of the drugs 
peaks.  
 
Figure 3: The peak purity without interference of Placebo and excipients 
Peak purity demonstrates that the observed chromatographic peak is attributed to a single 
component that the excipients were not interfering with the component peaks at the specific 
retention time.The acceptance criteria for the peak purity are to be attributed to 90 -100% purity. 
The impurities for pseudoephedrine are detected at 4.97 mins, 13.85 min for Guaiphenesin, 16.73 
mins for chlopheniramine and 52.38 mins for dextromethprphan giving rise to peak purity 
99.16%, 92.2%, 94.95% and 96.28% respectively. 
Thus, this demonstrates the method specificity. 
 
 
 
 
 
 
 
 
Linearity 
Table (2) Levels of concentration of Standard µg/ml 
 
 
 
ConcLevel  Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
1-5% 3 µg/ml 10 µg/ml 0.2 µg/ml 1 µg/ml 
2- 10% 6 µg/ml 20 µg/ml 0.4 µg/ml 2 µg/ml 
3- 25% 15 µg/ml 50 µg/ml 1 µg/ml 5 µg/ml 
4- 50% 30 µg/ml 100 µg/ml 2 µg/ml 10 µg/ml 
5- 75% 45 µg/ml 150 µg/ml 3 µg/ml 15 µg/ml 
6- 100% 60 µg/ml 200 µg/ml 4 µg/ml 20 µg/ml 
7- 125% 75 µg/ml 250 µg/ml 5 µg/ml 25 µg/ml 
8- 150% 90 µg/ml 300 µg/ml 6 µg/ml 30 µg/ml 
9- 175% 105 µg/ml 350 µg/ml 7 µg/ml 35 µg/ml 
10- 200% 120 µg/ml 400 µg/ml 8 µg/ml 40 µg/ml 
The Area versus concentration of the four compounds were tabulated as follows:  
Table (3) Peak area and RSD% for linearity 
 Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
Level Area  RSD% Area  RSD% Area  RSD% Area  RSD% 
1 164023.3 0.08 709131 0.24 15970.67 0.4 52153.33 0.89 
2 302652.3 0.08 1305768 0.06 22415.67 0.54 88761.67 0.38 
3 729054.7 0.04 3096022 0.03 54007 0.42 228668.7 0.25 
4 1488262 0.15 6191429 0.10 106605 0.38 480969.3 0.77 
5 2153761 0.19 8860252 0.31 162422 0.46 704803.7 0.53 
6 2853314 0.57 11555520 0.64 218128 0.92 938008 0.82 
7 3512556 0.03 14304351 0.02 267495.3 0.33 1159430 0.2 
8 4250768 0.88 17240602 0.35 324816 1.0 1402909 0.83 
9 4882828 0.04 19679804 0.04 371301 0.16 1613694.7 0.13 
10 5535872 0.24 22624204 0.26 427313 0.33 1888020 0.6 
Linearity Chromatograms 
 
 
 
Figure 4: Linearity Chromatograms 
Table (4) Linearity Results 
Parameter   Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
Correlation 0.9998 0.9996 0.9997 0.9997 
 
 
 
Coefficient r
2
 
Slope  46098.9590 55897.1449 53117.76 46687.1513 
y- intercept 56476.2818 337530.7956 2636.4341 1366.97 
Regression 
line equation 
Y= 46098.959 x 
+56476.2818 
Y= 55897.1449 
x + 
337530.7956 
Y= 53117.76 x + 
2636.4341 
Y= 46687.15 x + 
1366.97 
The acceptance criteria for the correlation Coefficient r
2
should be ≥ 0.999 for the range of 
concentration 75 – 125% of the target concentration. Thus, the method comply the requirement 
for linearity. 
Range 
The data obtained from the accuracy studies may be used to assess the range of the method. 50% 
to 150% of the target concentration is utilized. 
Limit of detection DL and limit of quantitation QL 
DL = 3.3 × The mean root square error MRSE / slope, QL = 10 ×MRSE / slope.  
DL µg/ml:  2.67, 10, 0.15, 0.86 for Pseudoephedrine, Guaifenesin, Chlorpheniramine, 
Dextromethorphan respectively.QL µg/ml: 8.08, 31.14, 0.47, 2.6. 
Accuracy 
According to the ICH guide lines Q2 the accuracy is assessed using three replicates of each of 
the concentrations 50%, 100% and 150% were analyzed for theoretical values, RSD and percent 
recovery. The following results were obtained: 
Table (5) Results for Accuracy 
Conc Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
 % Mean 
recovery 
RSD% % Mean 
recovery 
RSD% % Mean 
recovery 
RSD% % Mean 
recovery 
RSD% 
50% 100.85% 0.11% 100.94 0.01 100.74 0.07 99.71 0.56 
100% 100.85% 0.11% 99.43 0.16 100.41 0.16 100.21 0.18 
150% 100.83% 0.06% 99.39 0.06 100.73 0.48 100.12 0.19 
Since the acceptance criteria is that the measured recovery should be 95% - 105%, so the method 
comply the requirement for accuracy. 
Precision  
Repeatability 
10 replicates of the sample were used and the mean, stand deviation and relative standard 
deviation were obtained. 
Table (6) Repeatability Results 
 Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
 RT Area RT Area RT Area RT Area 
Mean  5.22 2890773 12.77 11780051 16.23 190932 51.71 179522 
RSD% 0.23% 0.2% 0.24% 0.25% 0.44% 0.27% 0.4% 0.19% 
  The FDA and ICH stated that the RSD should be ± 1% for the drug substance and ± 2% for the 
drug product. Thus, the method fulfilled the repeatability criterion. 
Intermediate Precision 
Intermediate precision within laboratory variations had been demonstrated by two analysts, using 
two HPLC systems on different days and evaluating the relative percent purity data across the 
two HPLC systems at three concentration levels; 50%, 100% and 150%. The following results 
were obtained: 
 
 
 
S1A and S1B is the RSD% of concentration 50% for analysts A and B. S2A and S2B is the RDS% 
of concentration 100% for analysts A and B. S3A and S3B is the RSD% of concentration 150% 
for analysts A and B. Two diffident systems at two different days technique were used. 
S2a + S2b are 0.52, 0.27, 0.09, and 0.17 for the four compounds respectively. 
S3a +S3b are 0.97, 1.0, 0.34, and 0.21 for the four compounds respectively. 
Since the acceptance criterion for intermediate precision is that the results obtained by two 
analysts using two instruments at different days should have statistical RSD ≤ 2%, thus the 
method comply the acceptable criteria. 
 
Robustness  
Effect of change in column temperature 
 
Table (7) Results of robustness on change in column temperature 
Variable Pseudoephedrine  Guaifenesin 
 Mean 
RT 
min 
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
 Mean 
RT 
min  
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
35 ͦC 5.27 2899252 50442 1.32 13.18 11790008 79212 1.25 
RSD% 00 0.08 0.2 0.4 0.03 0.08 0.19 0.14 
40 ͦC 5.19 2910793 50395 1.36 12.71 11790008 79086 1.26 
RSD% 0.25 0.39 0.55 0.19 0.22 0.8 0.49 0.08 
45 ͦC 5.1 2897807 49702 1.42 12.26 11790008 78530 1.26 
RSD% 00 0.08 0.2 0.04 0.03 0.08 0.19 0.14 
Variable  Chlorpheniramine Dextromethorphan  
 Mean 
RT 
min 
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
 Mean 
RT 
min  
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
35 ͦC 17 188365 88614 1.25 55.1 937097 85090 1.22 
RSD% 0.04 0.62 0.13 0.23 0.02 0.04 0.23 0.12 
40 ͦC 17.51 190058 88982 1.25 51.2 945921 87644 1.22 
RSD% 0.4 1.02 0.42 0.14 0.22 0.78 1.11 0.25 
45 ͦC 17.88 189603 88894 1.24 47.4 928239 91395 1.21 
RSD% 0.14 0.49 0.43 0.12 0.06 0.52 0.28 0.46 
 
Table (8) resolution of peaks at different Temperature 
Column 
temp 
Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
RT Resolution  RT Resolution  RT Resolution  RT Resolution  
35 ͦC 5.27 - 13.18 21.8 17 7.1 55.1 30 
40 ͦC 5.19 - 12.7 21.3 17.5 8.9 51.2 28 
55 ͦC 5.1 - 12.3 20.8 17.9 10.5 47.4 26.4 
 
 
 
 
 
 
 
 
 
 
Effect of change in the detective wavelength 
Table (9) Results of Change in the Wavelength 
Variable  Pseudoephedrine  Guaifenesin 
 Mean 
RT 
min 
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
 Mean 
RT 
min  
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
208 nm 5.22 3165558 51109 1.35 12.78 13490113 75159 1.26 
RSD% 0.07 0.3 0.55 00 0.08 0.24 0.2 0.05 
210 nm 5.22 2818701 50945 1.35 12.78 11838864 78557 1.25 
RSD% 0.07 0.29 0.55 0.04 0.08 0.26 0.02 0.05 
112 nm 5.22 2614346 50723 1.35 12.78 10609336 81459 1.25 
RSD% 0.07 0.27 0.56 0.04 0.08 0.29 0.03 0.05 
Variable  Chlorpheniramine Dextromethorphan  
 Mean 
RT 
min 
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
 Mean 
RT 
min  
Mean 
area 
Theoretical 
plates 
Tailing 
factor 
208 nm 17.66 208296 88796 1.25 51.5 1208256 85090 1.22 
RSD% 0.13 0.53 0.19 0.09 0.11 0.38 0.23 0.12 
210 nm 17.66 189909 88911 1.25 51.5 947748 86680 1.2 
RSD% 0.13 0.29 0.2 0.09 0.11 0.37 0.07 0.25 
112 nm 17.66 175248 89032 1.25 51.5 748245 86879 1.2 
RSD% 0.13 0.4 0.19 0.05 0.1 0.38 0.16 0.13 
Table () resolution of peaks at different Wavelengths 
Column 
temp 
Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
RT Resolution  RT Resolution  RT Resolution  RT Resolution  
208 nm 5.2 - 12.8 21 17.7 8.9 51.5 28 
210 nm 5.22 - 12.78 21.3 17.66 9 51.5 28 
212 nm 5.2 - 12.8 21.5 17.7 9.1 51.5 28 
 
Effect of change in the flow rate  
Table (10) Results of robustness on change of flow rate 
Variable  Pseudoephedrine  Guaifenesin 
 
Mean 
RT 
min 
Mean 
area 
Theoretica
l plates 
Tailin
g 
factor 
 Mean 
RT 
min  
Mean 
area 
Theoretical 
plates 
Tailin
g 
factor 
0.7 
ml/min 
5.89 329449
4 
55188 1.32 14.43 1338012
4 
84056 1.24 
RSD% 00 0.07 0.17 0.08 0.01 0.02 0.07 0.05  
0.8 
ml/min 
5.23 290840
9 
51315 1.35 12.8 1181023
9 
78508 1.25 
RSD% 0.05 0.19 0.36 0.13 0.05 0.12 0.1 0.09 
0.9 4.66 258257 45811 1.42 11.42 1047853 73876 1.26 
 
 
 
ml/min 1 4 
RSD% 0.26 0.24 1.1 0.19 0.24 0.26 1.3 0.23 
Variable  Chlorpheniramine Dextromethorphan  
 
Mean 
RT 
min 
Mean 
area 
Theoretica
l plates 
Tailin
g 
factor 
 Mean 
RT 
min  
Mean 
area 
Theoretical 
plates 
Tailin
g 
factor 
0.7 
ml/min 
19.86 213070 93639 1.24 57.9 1067617 90142 1.2 
RSD% 0.01 0.11 0.02 0.08 0.02 0.01 0.05 0.22 
0.8 
ml/min 
17.71 189127 89044 1.25 51.6 939955 86973 1.2 
RSD% 0.07 0.37 0.07 0.12 0.06 0.37 0.05 0.25 
0.9 
ml/min 
15.75 167279 85353 1.24 4.2 832535 86286 1.22 
RSD% 0.45 0.31 0.71 0.08 0.21 0.05 0.86 0.28 
 
Table (11)Resolution of peaks in changing the rate flow: 
Flow rate  Pseudoephedrine  Guaifenesin Chlorpheniramine Dextromethorphan 
RT Resolution  RT Resolution  RT Resolution  RT Resolution  
0.7 ml/min 5.9 - 14.
4 
22.1 19.9 9.2 57.9 28.6 
0.8 ml/min 5.2 - 12.
8 
21.4 17.7 9 51.6 28 
0.9 ml/min 5.2 - 12.
8 
20.5 17.7 8.8 51.5 27.9 
Acceptance Criteria for Robustness 
1- The number of the theoretical plates should be less than 2000. 
2- The tailing factor for compounds should not be more than 2.0. 
3- The RSD% of the peaks areas of the replicates of either the standard solution or the 
compounds should not be more than 2.0%. 
4- The resolution between the peaks of the compounds should be ≥ 2.0. 
The method fulfilled the acceptance criteria as the number of the theoretical plates in all 
variables is more than 2000, the RSD% of the retention time and peaks area are less than 2.0%, 
the tailing factor for all peaks of the different variables are less than 2.0 and the resolution 
between the peaks is more than 2.0. 
Thus, the method satisfied the requirements for robustness on changing the column temperature, 
on changing the detective wavelength and on changing the flow rate. 
Solution Stability 
The test had been carried out by initial testing then after preservation of the test solution for 6 
hours, 12 hours, 18 hours, 24 hours and 48 hours. 
Table (12). The average and RSD% of peak areas for solution stability 
Paramete Pseudoephedrin
e  
Guaifenesin Chlorpheniramin
e 
Dextromethorpha
n 
Mean peaks 2879033 11675642 187949 98897 
 
 
 
areas 
RSD% 0.12 0.19 0.15 0.48 
The RSD% for the peaks areas of all compounds is less than 2%, therefore, the standard 
preparation is stable for 48 hours at room temperature. 
Conclusion 
The analytical method used for determination of Pseudoephedrine HCL, Guaifenesin, 
Chlorpheniramine Maleate and Dextromethorphan HBr in AD- solution as four-in-one was 
found to be consistent and precise and in conformance with the acceptable criteria of validation 
parameters of specificity, system suitability, linearity and range, precision, accuracy, 
reproducibility and robustness. The method is fully validated and can be used in routine testing 
for simultaneous determination of such combination products. 
Acknowledgement 
The team and manager of Blue Nile Research Centre were greatly acknowledged for their great 
support and encouragement.  
References 
1. United States Pharmacopeia2013 ,USP 39 - The National Formulary, 1/5/2016, 12601 
Twinbrook Parkway, Rockville, MD 2052, USP Volume 1 p 1641, volume 2, p 2310, 
4164 volume 2. 
( tablet containing at least three of the following – acetaminophen chlorpheniramine, 
dextromethorphan and pseudoephedrine. 
2. ICH Q2 validation of analytical procedures Part 2, 6/1995, ICH, Guidance for Industry 
Q1A(R2) Stability Testingof  New Drug Substances and Products,2003., 
www.emea.eu.int 
3. Wikipedia, www.en.wikipedia.org 25/10/2020, 13:00 
4. . British National Formulary 80, September 2020, Royal Pharmaceutical Society, 
published by BMI Group and Pharmaceutical Press, p 221, www.pharmapress.com 
5. PrayasAcharya, T Prasanth Kumar, Immanuel Agasteen, SreeramaRajasekhar and G 
Neelima, 2017, A review on Analytical Methods for Determination of Guaifenesin Alone 
and in Combination with other Drugs in Pharmaceutical Formulation, Saudi Journal of 
Medical and Pharmaceutical Sciences, DIO: 10.21276/sjmps.2017.3.3.7, 
http://scholarsmepub.com. 
6. Validation of Analytical Methods and Processes- Ludwig Huber, Agilent Technologies 
GmbH, Waldbronn, Germanyp 544 
7. FDA Guidance for Industry, Analytical Procedures and Method Validation for Drugs and 
Biologics, July 2015. 
